Table 3. Prevalence of hallucinations by thirds of plasma CRP.
| Plasma CRP | ||||||||
| bottom third | middle third | top third | ||||||
| <0.2 mg/L | 0.3–0.6 mg/L | 0.7 mg/L< | p | |||||
| Hallucinations | Yes, n (%) | 5 | (13.2%) | 8 | (21.6%) | 15 | (41.7%) | 0.005 |
| No, n (%) | 33 | (86.8%) | 29 | (78.4%) | 21 | (58.3%) | ||
| UPDRS-3 | mean (SD) | 21.2 | (10.1) | 23.6 | (11.4) | 23.9 | (10.2) | 0.44 |
| MMSE | mean (SD) | 28.3 | (2.0) | 27.7 | (2.0) | 26.4 | (3.5) | 0.002 |
| Age (Y) | mean (SD) | 67.2 | (7.8) | 70.8 | (7.3) | 71.1 | (7.9) | 0.05 |
| DA agonist (LDED, mg/day) | median (IQR) | 83.5 | (0–168) | 67.0 | (0–200) | 71.0 | (0–134) | 0.70 |
| L-Dopa (mg/day) | mean (SD) | 435.5 | (183.2) | 412.8 | (185.7) | 456.3 | (170.0) | 0.59 |
| PPQ-A score | median (IQR) | 1 | (0–2) | 0 | (0–1) | 1 | (0–2) | 0.09 |
p was calculated using Chi-square test for hallucinations (p for trend), ANOVA for UPDRS-3, MMSE, age, L-Dopa, Kruskal-Wallis test for DA agonist and PPQ-A score.